282 related articles for article (PubMed ID: 6248200)
1. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
Platica M; Bojko C; Steiner G; Hollander VP
Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
[TBL] [Abstract][Full Text] [Related]
2. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
Osborne DP; Katz DH
J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
[TBL] [Abstract][Full Text] [Related]
3. Transplantation of primary plasma cell tumor without 2,6,10,14- tetramethylpentadecane (pristane) treatment of the hosts.
Platica M; Bojko C; Hollander VP
Cancer Res; 1980 Mar; 40(3):579-81. PubMed ID: 7471077
[TBL] [Abstract][Full Text] [Related]
4. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
[No Abstract] [Full Text] [Related]
5. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction.
Osborne DP; Katz DH
J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034
[TBL] [Abstract][Full Text] [Related]
6. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
Kleinman R; Dray S
Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
[TBL] [Abstract][Full Text] [Related]
7. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
Cihak J; Ziegler HW; Kölsch E
Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
[TBL] [Abstract][Full Text] [Related]
8. Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice.
McDonald AH; Degrassi A
Cell Immunol; 1993 Jan; 146(1):157-70. PubMed ID: 8425224
[TBL] [Abstract][Full Text] [Related]
9. Preparation and properties of an antiplasma cell serum directed against a defined plasmacytoma cell population.
Proctor ML; Herscowitz HB
J Immunol; 1975 Dec; 115(6):1642-9. PubMed ID: 1184969
[TBL] [Abstract][Full Text] [Related]
10. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
11. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
12. Examination of general and tumor-specific cell-mediated immune responses in mice bearing progressively growing plasmacytomas.
Padarathsingh ML; McCoy JL; Dean JH; Lewis DD; Northing JW; Law LW
J Natl Cancer Inst; 1977 Jun; 58(6):1701-7. PubMed ID: 301196
[No Abstract] [Full Text] [Related]
13. Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: a possible mechanism of defence.
Bomstein Y; Ophir R; Harshemes H; Ben-Efraim S
Anticancer Res; 1993; 13(6A):2125-9. PubMed ID: 8297124
[TBL] [Abstract][Full Text] [Related]
14. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
15. The effect of adherent peritoneal exudate cells (APECs) and their products on the RPC-5 plasmacytoma growth in vitro.
Salwa J
Arch Immunol Ther Exp (Warsz); 1990; 38(3-4):267-74. PubMed ID: 2102659
[TBL] [Abstract][Full Text] [Related]
16. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
17. [Effect of the cell dose on the development of 2 transplantable tumors in a syngeneic host].
Pugliese A; Choc O
G Batteriol Virol Immunol; 1976; 69(1-6):122-31. PubMed ID: 15919
[TBL] [Abstract][Full Text] [Related]
18. An experimental model for evaluation of factors in tumor escape from immunological attack.
Yutoku M; Fuji H; Grossberg AL; Pressman D
Cancer Res; 1975 Mar; 35(3):734-9. PubMed ID: 1116132
[TBL] [Abstract][Full Text] [Related]
19. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
Lubet RA; Carlson DE
J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
[TBL] [Abstract][Full Text] [Related]
20. [Cytological profile of the thymus from mice with increased resistance to the growth of plasmacytoma P3-X63-Ag8.653-MOPC during stress].
Volkova LV; Furduĭ FI; Sapin MR; Aminova GG; Grigorenko DE; Erofeeva LM; Rusina AK
Biull Eksp Biol Med; 1994 May; 117(5):454-6. PubMed ID: 9296685
[No Abstract] [Full Text] [Related]
[Next] [New Search]
